Objective: HIV dementia is an important neurological complication of advanced HIV infection. The use of a cross-cultural screening test to detect HIV dementia within the international community is critical for diagnosing this condition. The objective of this study was to evaluate the sensitivity and specificity of a new screening test for HIV dementia, the International HIV Dementia Scale (IHDS) in cohorts from the US and Uganda.
Design: Two cross-sectional cohort studies designed to evaluate for the presence of HIV dementia.
Methods: Sixty-six HIV-positive individuals in the US and 81 HIV-positive individuals in Uganda received the IHDS and full standardized neurological and neuropsychological assessments. The sensitivity and specificity of varying cut-off scores of the IHDS were evaluated in the two cohorts.
Results: In the US cohort, the mean IHDS score for HIV-positive individuals without dementia and with dementia were 10.6 and 9.3 respectively (P < 0.001). Using the cut-off of < or = 10, the sensitivity and specificity for HIV dementia with the IHDS were 80% and 57% respectively in the US cohort, and 80% and 55% respectively in the Uganda cohort.
Conclusions: The IHDS may be a useful screening test to identify individuals at risk for HIV dementia in both the industrialized world and the developing world. Full neuropsychological testing should then be performed to confirm a diagnosis of HIV dementia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Advances in assessment and cognitive neurorehabilitation of HIV-related neurocognitive impairment.
Brain Commun
December 2024
NeuroScape@NeuroTech Lab, Service Universitaire de Neuroréhabilitation (SUN), Département des Neurosciences Cliniques, Centre Hosoitalier Universitaire Vaudois (CHUV), Institution de Lavigny, University of Lausanne, 1011 Lausanne, Switzerland.
Neurocognitive impairment (NCI) is present in around 40% of people with HIV and substantially affects everyday life, adherence to combined antiretroviral therapy (cART) and overall life expectancy. Suboptimal therapy regimen, opportunistic infections, substance abuse and highly prevalent psychiatric co-morbidities contribute to NCI in people with HIV. In this review, we highlight the need for efficacious treatment of HIV-related NCI through pharmacological approaches and cognitive neurorehabilitation, discussing recent randomized controlled trials in this domain.
View Article and Find Full Text PDFHypertension and orthostatic hypotension in the elderly: a challenging balance.
Lancet Reg Health Eur
January 2025
Department of Internal Medicine, Section Geriatrics, Amsterdam UMC, Boelelaan 1117, Amsterdam, the Netherlands.
Hypertension and orthostatic hypotension (OH) frequently coexist in the older population, both stemming from impaired blood pressure (BP) regulation. Managing hypertension in patients with OH presents a significant clinical challenge, particularly in frail older adults who are also prone to falls. Hypertension treatment is often suboptimal in this population due to concerns over the potential increased risk of falls associated with treatment.
View Article and Find Full Text PDFDiscovery of Dual Targeting GSK-3β/HIV-1 Reverse Transcriptase Inhibitors as Neuroprotective Antiviral Agents.
ACS Chem Neurosci
December 2024
Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
Glycogen synthase kinase-3 beta (GSK-3β or GSK-3B) is a serine-threonine kinase involved in various pathways and cellular processes. Alteration in GSK-3β activity is associated with several neurological diseases including Alzheimer's disease (AD), bipolar disorder, and rare diseases like Rett syndrome. GSK-3β is also implicated in HIV-associated dementia (HAD), as it is upregulated in HIV-1-infected cells and plays a role in neuronal dysfunction.
View Article and Find Full Text PDFArticle Synopsis
- HIV significantly affects neurocognitive function in Africa, leading to high prevalence rates of neurocognitive disorders, with Central and South Africa showing the highest impairment levels (around 49.33%).
- Variability in neurocognitive impairment prevalence is influenced by factors like ART availability, healthcare infrastructure, and co-infections, emphasizing the need for targeted interventions.
- Addressing this issue requires collaboration among healthcare providers, policymakers, and communities, focusing on education, early detection, improved resources, and research partnerships to better support individuals living with HIV.
Clustering of cognitive domains among older persons with HIV.
Gac Med Mex
November 2024
Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Article Synopsis
- - The study investigated the cognitive profiles of older people with HIV (OPWH) undergoing combined antiretroviral therapy, focusing on how age interacts with HIV-related cognitive disorders.
- - Researchers conducted a cross-sectional analysis of 330 OPWH aged 50 and older, using neuropsychological tests to evaluate cognitive functions and identify clusters of cognitive impairment.
- - Results showed three distinct cognitive clusters: one with significant memory impairments, another with language and abstraction issues, and a third with no specific domain impairments, suggesting variations based on both HIV-related and other individual factors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!